African swine fever virus (ASFV) has been traditionally a major animal health problem worldwide, with important economic impact for the pig industry. Recently the disease has re-emerged in large areas of the world, including China and Eastern Europe. Therefore, it seems timely to summarize our current understanding of ASFV proteins and their antigenic properties, in connection with potential vaccine formulations. Here we review the main characteristics of the major structural proteins p150, p72 and p17 of ASFV and their antigenic properties. In particular, we emphasize that p17 was detected as a specific antigen in the immunoreaction of pig sera with neutralizing antibodies. In addition, specific immunoreactions against IP97, IP27, IP25.5, IP23 and IP13 viral infection proteins were also detected in these sera. The viral structural proteins have been studied with intracellular and extracellular viruses and, therefore the differences between both classes of viruses were also reviewed.

Dengue virus is an arbovirus belonging to class Flaviviridae Its clinical manifestation ranges from asymptomatic to extreme conditions (dengue hemorrhagic fever/dengue shock syndrome). A lot of research has been done on this ailment, yet there is no effective treatment available for the disease. This review provides the systematic understanding of all dengue proteins, role of its structural proteins (C-protein, E-protein, prM) in virus entry, assembly, and secretion in host cell, and nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) in viral assembly, replication, and immune evasion during dengue progression and pathogenesis. Furthermore, the review has highlighted the controversies related to the only commercially available dengue vaccine, that is, Dengvaxia, and the risk associated with it. Lastly, it provides an insight regarding various approaches for developing an effective anti-dengue treatment.

The goals of molecular virology and immunology during the second half of the 20th century have been to provide the conceptual approaches and the tools for the development of safe and efficient virus vaccines for the human population. The success of the vaccination approach to prevent virus epidemics was attributed to the ability of inactivated and live virus vaccines to induce a humoral immune response and to produce antiviral neutralizing antibodies in the vaccinees. The successful development of antiviral vaccines and their application to most of the human population led to a marked decrease in virus epidemics around the globe. Despite this remarkable achievement, the developing epidemics of HIV-caused AIDS (accompanied by activation of latent herpesviruses in AIDS patients), epidemics of Dengue fever, and infections with respiratory syncytial virus may indicate that conventional approaches to the development of virus vaccines that induce antiviral humoral responses may not suffice. This may indicate that virus vaccines that induce a cellular immune response, leading to the destruction of virus-infected cells by CD8+ cytotoxic T cells (CTLs), may be needed. Antiviral CD8+ CTLs are induced by viral peptides presented within the peptide binding grooves of HLA class I molecules present on the surface of infected cells. Studies in the last decade provided an insight into the presentation of viral peptides by HLA class I molecules to CD8+ T cells. These studies are here reviewed, together with a review of the molecular events of virus replication, to obtain an overview of how viral peptides associate with the HLA class I molecules. A similar review is provided on the molecular pathway by which viral proteins, used as subunit vaccines or inactivated virus particles, are taken up by endosomes in the endosome pathway and are processed by proteolytic enzymes into peptides that interact with HLA class II molecules during their transport to the plasma membrane of antigen-presenting cells. Such peptides are identified by T-cell receptors present on the plasma membrane of CD4+ T helper cells. The need to develop viral synthetic peptides that will have the correct amino acid motifs for binding to HLA class I A, B, and C haplotypes is reviewed. The development of HIV vaccines that will stimulate, in an uninfected individual, the humoral (antibody) and cellular (CTL) immune defenses against HIV and HIV-infected cells, respectively, and may lead to protection from primary HIV infection are discussed.(ABSTRACT TRUNCATED AT 400 WORDS)

暂无摘要。

暂无摘要。

暂无摘要。

Since its discovery in 1983, a lot of knowledge about the human immunodeficiency virus (HIV) has been accumulated. Our paper gives a brief survey on what is known at present about the structure, molecular biology, and the cell tropism of this virus. We discuss its relationship to other lentiviruses as well as its possible origin; in addition, we refer to the immune response to HIV and its interactions with the infected host. We also briefly summarize the difficulties encountered in the attempts to produce a vaccine against HIV and highlight some promising approaches in the development of such a vaccine.

Although human cytomegalovirus (HCMV) has a genome of 150 x 10(6) Da, and a protein-coding content of over 200 open reading frames, few viral proteins seem able to elicit a strong antibody response in the natural host during viral infection. The immunodominant polypeptides include a component of 72 kDa among immediate early proteins, a polypeptide of 52 kDa among delayed early proteins and a glycoprotein complex of 58 and 93-130 kDa and two phosphoproteins of mol. wt 150 and 65 kDa among the structural proteins. Following a general overview of the humoral immune response, this brief survey mainly deals with the antibody response to these proteins. As significant epitopes of the major HCMV immunogenic polypeptides have been expressed in procaryotic cells over the last few years, an overview of the state of the art in this particular field will also be given.